Overview

• GSK will pay $1 billion upfront and up to $150 million in milestone payments to acquire Massachusetts-based IDRx.
• IDRx specializes in therapies for gastrointestinal stromal tumors (GIST), a rare digestive system cancer affecting tens of thousands globally each year.
• The deal includes IDRx's lead experimental drug, IDRX-42, which targets mutations in the KIT gene linked to tumor growth and has shown promise in early clinical trials.
• GSK aims to accelerate the development of IDRX-42 in 2025, potentially redefining treatment options for GIST patients after two decades without significant advancements.
• This acquisition aligns with GSK's strategy to expand its oncology portfolio and address unmet medical needs in gastrointestinal cancers.